Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans.

Ulrichts P, Guglietta A, Dreier T, van Bragt T, Hanssens V, Hofman E, Vankerckhoven B, Verheesen P, Ongenae N, Lykhopiy V, Enriquez FJ, Cho J, Ober RJ, Ward ES, de Haard H, Leupin N.

J Clin Invest. 2018 Oct 1;128(10):4372-4386. doi: 10.1172/JCI97911. Epub 2018 Jul 24.

2.

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy.

Godar M, Morello V, Sadi A, Hultberg A, De Jonge N, Basilico C, Hanssens V, Saunders M, Lambrecht BN, El Khattabi M, de Haard H, Michieli P, Blanchetot C.

Sci Rep. 2016 Aug 22;6:31621. doi: 10.1038/srep31621.

3.

GDF15/MIC1 and MMP9 Cerebrospinal Fluid Levels in Parkinson's Disease and Lewy Body Dementia.

Maetzler W, Deleersnijder W, Hanssens V, Bernard A, Brockmann K, Marquetand J, Wurster I, Rattay TW, Roncoroni L, Schaeffer E, Lerche S, Apel A, Deuschle C, Berg D.

PLoS One. 2016 Mar 3;11(3):e0149349. doi: 10.1371/journal.pone.0149349. eCollection 2016.

4.

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling.

Hultberg A, Morello V, Huyghe L, De Jonge N, Blanchetot C, Hanssens V, De Boeck G, Silence K, Festjens E, Heukers R, Roux B, Lamballe F, Ginestier C, Charafe-Jauffret E, Maina F, Brouckaert P, Saunders M, Thibault A, Dreier T, de Haard H, Michieli P.

Cancer Res. 2015 Aug 15;75(16):3373-83. doi: 10.1158/0008-5472.CAN-15-0356. Epub 2015 Jul 3.

5.

Four individually druggable MET hotspots mediate HGF-driven tumor progression.

Basilico C, Hultberg A, Blanchetot C, de Jonge N, Festjens E, Hanssens V, Osepa SI, De Boeck G, Mira A, Cazzanti M, Morello V, Dreier T, Saunders M, de Haard H, Michieli P.

J Clin Invest. 2014 Jul;124(7):3172-86. doi: 10.1172/JCI72316. Epub 2014 May 27.

Supplemental Content

Loading ...
Support Center